CSF2 and leukemia: The conversion of leukemic blasts into antigen-presenting dendritic cells of leukemic origin (DC<sub>leu</sub>) by GM-CSF and PGE1 has demonstrated preclinical efficacy in eliciting leukaemia-specific immune responses, offering a promising immunotherapeutic strategy for relapsed/refractory AML.